Floatz logo

RITONAVIR

Long COVID-19

Kanecia Obie ZimmermanSmall moleculePhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

31 Active assets in the Long COVID-19 cohort.

Asset / SponsorPhaseRating
Immulina Tm
University of Mississippi Medical Center
Phase 3BB
Paxlovid
Kanecia Obie Zimmerman
Phase 2B
MELATONIN
Duke University
Phase 2B
Rapamycin
Icahn School of Medicine at Mount Sinai
Phase 3B
IVABRADINE
Kanecia Obie Zimmerman
Phase 2B

View all 31 →

Same molecule, other indications

RITONAVIR is also rated in:

chronic hepatitis C virus infectionDormant
BBB
Indicative ·
76 / 100
View asset →
hepatitis C virus infectionDormant
BBB
Indicative ·
76 / 100
View asset →
HIV infectious diseaseDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →